Landmark trial
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Perry JR, Laperriere N, O’Callaghan CJ, et al. · CCTG / EORTC / TROG
DoseLab summary
Phase 3 trial in patients 65 or older with glioblastoma: 40 Gy in 15 fractions with temozolomide improved survival compared with the same radiotherapy alone. Citation checked against Crossref.
Why this is useful
The trial behind short-course chemoradiation for older patients.
Reference details
- Title
- Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
- Authors / organization
- Perry JR, Laperriere N, O’Callaghan CJ, et al. · CCTG / EORTC / TROG
- Publication / protocol
- N Engl J Med. 2017;376(11):1027–1037
- Version
- Pending verification
- Year
- 2017
- DOI
- 10.1056/NEJMoa1611977
- Disease sites
- CNS / Brain
- Topics
- Glioma, Glioblastoma, Hypofractionation, Chemoradiation, Landmark trial
- Fractionation context
- 40 Gy / 15 fx
- Last reviewed by DoseLab
- Pending verification